On August 2, 2022 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, reported that it will host a conference call on Tuesday, August 9th, 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022 (Press release, Infinity Pharmaceuticals, AUG 2, 2022, View Source [SID1234617245]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity’s website at View Source and will be available on Infinity’s website for 30 days following the event.

On August 2, 2022 ChromaDex Corp. (NASDAQ:CDXC) reported that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2022 (Press release, ChromaDex, AUG 2, 2022, View Source [SID1234617243]). The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conference Call:

ChromaDex management will host an investor conference call to discuss the second quarter results and provide a general business update on Wed., August 10, at 4:30 p.m. ET.

Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

A replay of the conference call will be available from 7:30 p.m. ET on August 10, 2022, to 11:59 p.m. ET on August 17, 2022.

On August 2, 2022 ADC Therapeutics SA (NYSE: ADCT) reported that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report financial results for the second quarter 2022 and provide business updates (Press release, ADC Therapeutics, AUG 2, 2022, View Source [SID1234617242]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

On August 2, 2022 JSR Corporation reported that acceleration of its co-development with SK hynix Inc. to apply Inpria, a JSR company’s Extreme Ultraviolet (EUV) metal oxide resist (MOR) for manufacturing advanced DRAM chips (Press release, JSR, AUG 2, 2022, View Source [SID1234617238]). Inpria’s broadly-patented metal oxide photoresist platform for EUV enables customers to efficiently pattern advanced node device architectures.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Inpria material solutions provide the performance needed to significantly reduce the cost of EUV patterning and are compatible with proven processes and equipment configurations. Inpria’s MOR can be applied by a standard spin coating process.

"EUV manufacturing is complex and requires cutting-edge materials," said BK Lee, head of R&D process at SK hynix. "Tin-oxide resists show promise to deliver both on performance and also on lower manufacturing cost for the next generation of state-of-the-art DRAM."

"JSR’s technology has always been based on materials innovation," said Tadahiro Suhara, Managing Officer at JSR. "We are committed to accelerating SK hynix’s technology roadmap by enabling efficient printing of the smallest features. The science is pioneering but so are the economics."

EUV is already in use in commercial production in the most advanced lithography processes used in semiconductor manufacturing and, as the industry moves to smaller critical dimensions in chip manufacturing, its use is expected to increase substantially.

Inpria is the leader in metal oxide EUV resists and has achieved the world’s highest resolution using EUV exposure systems. JSR acquired Inpria 2021 and, as EUV adoption continues to increase, is investing in expanding production capabilities and customer support services for high volume manufacturing.

On August 2, 2022 KYORIN Holdings, Inc. reported that KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyodaku, Tokyo; President & CEO: Shigeru Ogihara, hereinafter KYORIN), a subsidiary of KYORIN Holdings, Inc., passed at its Board of Directors meeting on August 2, 2022 a resolution on the termination and dissolution of business of ActivX Biosciences, Inc. (President and CEO: Hugh Rosen, hereinafter ActivX) by March 31, 2023 (Press release, Kyorin, AUG 2, 2022, View Source [SID1234617237]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In 2004, KYORIN acquired ActivX, which was formerly a bio venture company with a unique proteomics technology, as a wholly owned subsidiary, and KYORIN has utilized ActivX’s technology to improve efficiency and speed of the exploratory research of pharmaceutical candidates. In recent years, a collaboration between KYORIN and ActivX, with the use of ActivX’s KiNativTM (comprehensive kinase profiling in situ), as a platform technology as well as KYORIN’s analytical technology in disease modeling and its small molecule drug discovery technology, has led to discovery of novel pharmaceutical targets and candidates, and enhancement of, in terms of both quantity and quality, early stage discovery research programs. As drug discovery technologies continue to advance and diversify, KYORIN has determined that ActivX has fulfilled its certain role in small molecule drug discovery and has decided to terminate the business of ActivX, as a result of the examination of efficiency and productivity of KYORIN’s investment in drug discovery.

The impact of this event on the consolidated financial forecast for the fiscal year ending in March, 2023 will be minor.